A5009499168- Hepatitis C virus research
- Liver Disease Diagnosis and Treatment
- Hepatitis B Virus Studies
- HIV/AIDS drug development and treatment
- HIV/AIDS Research and Interventions
- HIV, Drug Use, Sexual Risk
- HIV Research and Treatment
- SARS-CoV-2 and COVID-19 Research
- HIV-related health complications and treatments
- COVID-19 Clinical Research Studies
- Influenza Virus Research Studies
- Liver Disease and Transplantation
- Pneumocystis jirovecii pneumonia detection and treatment
- Respiratory viral infections research
- Systemic Lupus Erythematosus Research
- Vaccine Coverage and Hesitancy
- Long-Term Effects of COVID-19
- Immunotherapy and Immune Responses
- COVID-19 Impact on Reproduction
- Immune Response and Inflammation
- Chronic Lymphocytic Leukemia Research
- Alcohol Consumption and Health Effects
- Viral gastroenteritis research and epidemiology
- Adolescent Sexual and Reproductive Health
- Immune Cell Function and Interaction
University of Ottawa
2016-2025
Ottawa Hospital
2016-2025
Ottawa Hospital Research Institute
2016-2025
Institute of Infection and Immunity
2020-2024
Canadian Respiratory Research Network
2024
Response Biomedical (Canada)
2022-2024
Toronto Metropolitan University
2024
Wilfrid Laurier University
2024
University of Calgary
2016-2024
University of Toronto
2010-2023
In phase 2 trials, treatment with the combination of nucleotide polymerase inhibitor sofosbuvir and NS5A velpatasvir resulted in high rates sustained virologic response patients chronically infected hepatitis C virus (HCV) genotype or 3.We conducted two randomized, 3, open-label studies involving who had received previous for HCV 3 those not such treatment, including compensated cirrhosis. one trial, were randomly assigned a 1:1 ratio to receive sofosbuvir-velpatasvir, once-daily, fixed-dose...
The interferon-free regimen of ABT-450 with ritonavir (ABT-450/r), ombitasvir, and dasabuvir or without ribavirin has shown efficacy in inducing a sustained virologic response phase 2 study involving patients hepatitis C virus (HCV) genotype 1 infection. We conducted two 3 trials to examine the safety this previously untreated HCV infection no cirrhosis.
Patients who are chronically infected with hepatitis C virus (HCV) and do not have a sustained virologic response after treatment regimens containing direct-acting antiviral agents (DAAs) limited retreatment options.We conducted two phase 3 trials involving patients had been previously treated DAA-containing regimen. In POLARIS-1, HCV genotype 1 infection received regimen an NS5A inhibitor were randomly assigned in 1:1 ratio to receive either the nucleotide polymerase sofosbuvir,...
Effective treatment for hepatitis C virus (HCV) in patients coinfected with human immunodeficiency type 1 (HIV-1) remains an unmet medical need.We conducted a multicenter, single-group, open-label study involving HIV-1 and genotype or 4 HCV receiving antiretroviral regimen of tenofovir emtricitabine efavirenz, rilpivirine, raltegravir. All received ledipasvir, NS5A inhibitor, sofosbuvir, nucleotide polymerase as single fixed-dose combination 12 weeks. The primary end point was sustained...
Background: Little is known about the effect of combination antiretroviral therapy (cART) on life expectancy in sub-Saharan Africa. Objective: To estimate patients once they initiate cART Uganda. Design: Prospective cohort study. Setting: Public sector HIV and AIDS disease-management program Patients: 22 315 eligible initiated during study period, whom 1943 were considered to have died. Measurements: All-cause mortality rates calculated abridged tables constructed stratified by sex baseline...
Drug use is associated with increased morbidity and mortality but people who drugs experience significant barriers to care. Data are needed about the care experiences of inform interventions quality improvement initiatives. The objective this study describe characterize acute for drugs.We conducted a qualitative descriptive study. We recruited history active drug at time an admission hospital, were living HIV or hepatitis C, in Toronto Ottawa, Canada. collected 2014 2015 through...
Abstract Humoral responses to COVID-19 vaccines in people living with HIV (PLWH) remain incompletely characterized. We measured circulating antibodies against the SARS-CoV-2 spike protein receptor-binding domain (RBD), ACE2 displacement and viral neutralization activities one month following first second vaccine doses, again 3 months dose, 100 adult PLWH 152 controls. All were receiving suppressive antiretroviral therapy, median CD4+ T-cell counts of 710 (IQR 525–935) cells/mm , though nadir...
Background: HIV patients are vaccine hyporesponsive. Methods: We evaluated CPG 7909, a synthetic oligodeoxynucleotide containing immunostimulatory CpG motifs, as an adjuvant to Engerix-B. A randomized, double-blind controlled trial was conducted determine safety and hepatitis B virus (HBV) immunogenicity in adult subjects on effective antiretroviral therapy. HBV-susceptible subjects, half of whom had failed previous vaccination, were vaccinated at 0, 1 2 months with double dose Engerix-B...
We sought to evaluate life expectancy and mortality of HIV-positive individuals initiating combination antiretroviral therapy (ART) across Canada, consider the potential error introduced by participant loss follow-up (LTFU).Our study used data from Canadian Observational Cohort (CANOC) collaboration, including aged ≥18 years who initiated ART on or after January 1, 2000. The CANOC collaboration collates eight sites in British Columbia, Ontario, Quebec. computed abridged life-tables remaining...
(See the editorial commentary by Taiwo and Bosch, on pages 1189–91.) Background. The importance of human immunodeficiency virus (HIV) blip magnitude virologic rebound has been raised in clinical guidelines relating to viral load assays. Methods. Antiretroviral-naive individuals initiating combination antiretroviral therapy (cART) after 1 January 2000 achieving suppression were studied. Negative binomial models used identify correlates. Recurrent event determine association between blips...
•Sofosbuvir/velpatasvir (SOF/VEL) is approved for patients with HCV infection.•There no dosing recommendation SOF-based regimens HCV-infected on dialysis.•We evaluated SOF/VEL 12 weeks in end-stage renal disease dialysis.•SOF/VEL was safe and well tolerated, a cure rate of 95% our study. Background & AimsAlthough off-label use sofosbuvir-containing occurs regularly hepatitis C virus (HCV) infection undergoing dialysis severe impairment or (ESRD), these are not licensed this indication, there...
[See related article at [www.cmaj.ca/lookup/doi/10.1503/cmaj.170931][2]][2] KEY POINTS Chronic hepatitis C virus (HCV) is a highly burdensome public health problem in Canada, causing more years of life lost than any other infectious disease the country. [1][2]–[3][3] A recent modelling study
Abstract Objective Post COVID-19 condition refers to persisting or recurring symptoms weeks after acute illness which can significantly impact quality of life and health systems. It is important understand the manifestation magnitude this condition. The objective living systematic review summarize prevalence sequelae reported by people ≥4 diagnosis. Design Systematic review, meta-analysis narrative synthesis. Data sources Embase, Medline, PsychInfo, Cochrane Central select grey literature up...